Abstract
The INT 0123 trial demonstrated no benefit to dose escalation above 50.4 Gy for definitive chemoradiotherapy (CRT). Two randomized trials comparing CRT to trimodality therapy (TMT) use doses of 40-46 Gy for TMT and 65-66 Gy for CRT. Patients in these trials were predominately of squamous histology which does not reflect the U.S. population. We thus examined the effects of dose on outcomes for esophageal cancer patients taking into consideration histology and treatment modality.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
